核酸増幅検査市場：技術別、用途別-世界予測2025-2030年

核酸増幅検査市場は、2023年に31億3,000万米ドルと評価され、2024年には35億3,000万米ドルに達すると予測され、CAGR 12.86％で成長し、2030年には73億米ドルになると予測されています。

核酸増幅検査（NAAT）は、DNAまたはRNAの特定の配列を増幅・検出するために使用される重要な分子技術であり、感染症、遺伝性疾患、がんの診断に極めて重要です。NAATの必要性は、その高い感度と特異性からきており、病気の効果的な治療と封じ込めに不可欠な早期発見と正確な診断を可能にします。その用途はヘルスケア、バイオテクノロジー、医薬品に及び、診断、研究開発において重要な役割を果たしています。最終用途には、病院、診断研究所、研究機関、バイオ製薬会社などが含まれます。市場成長の原動力は、感染症の蔓延、技術の進歩、個別化医療に対する需要の高まりです。COVID-19のパンデミックは、NAATをウイルス検出のための不可欠なツールとして位置づけ、認識と採用を大幅に高めました。新たなビジネスチャンスは、スループットと精度を向上させるための自動化とデジタル技術の継続的な統合にあり、ポイントオブケア（POC）診断の範囲を拡大することでもあります。しかし、市場の成長は、高コスト、複雑な規制状況、熟練した人材の必要性などの課題に直面しています。企業は研究開発に投資してコストを下げ、特に十分なサービスを受けていない地域におけるアクセシビリティを向上させることで、チャンスを生かすことができます。ヘルスケア機関との協力やトレーニングプログラムへの投資により、いくつかの課題を軽減することができます。技術革新が必要な分野には、POC検査用の携帯可能で使いやすいキットの開発やリアルタイム分析機能などがあります。また、遠隔医療やデジタルヘルス技術を活用して検査プロセスやデータ管理を合理化することで、事業の成長に拍車をかけることもできます。市場競争は激しく、市場シェアを効果的に獲得するためには、急速な技術革新に対応する機敏さと戦略的パートナーシップが必要となります。企業は、既存の限界に対処しつつ、増大する需要に対応するため、持続可能性と費用対効果に重点を置かなければならないです。環境モニタリングや農業診断など、疾病検出以外の新規アプリケーションを開拓することで、さらなる市場の可能性が開けるかもしれないです。

市場力学：急速に進化する核酸増幅検査市場の主要市場インサイトを公開

核酸増幅検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • COVID-19およびその他の感染性細菌ウイルスの発生率の上昇
  • 新しいバイオテクノロジー診断薬開発への投資の増加
  • 診断施設・研究所の拡大
• 市場抑制要因
  • バイオテクノロジー診断に課される政府の厳しい規制
• 市場機会
  • NAA検査における新たな技術改良
  • NAA検査を促進する政府の好意的な取り組み
• 市場の課題
  • 訓練された専門技術者の不足と高い感度

ポーターの5つの力：核酸増幅検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：核酸増幅検査市場における外部からの影響の把握

外部マクロ環境要因は、核酸増幅検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析核酸増幅検査市場における競合情勢の把握

核酸増幅検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス核酸増幅検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、核酸増幅検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨核酸増幅検査市場における成功への道筋を描く

核酸増幅検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • COVID-19やその他の感染性細菌ウイルスの発生率上昇
    • 新しいバイオテクノロジー診断の開発への投資増加
    • 診断施設と検査室の数の拡大
  • 抑制要因
    • 核酸増幅検査に課せられた厳しい政府規制
  • 機会
    • NAA試験における新たな技術的改善
    • NAA試験を促進するための政府の好ましい取り組み
  • 課題
    • 訓練された技術的専門知識と高い感受性の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 核酸増幅検査市場：技術別

• プローブ増幅システム
• 信号増幅システム
• ターゲット増幅システム

第7章 核酸増幅検査市場：用途別

• がん
• 遺伝性疾患およびミトコンドリア疾患
• 感染症
  • 細菌性
  • バイラル
• パーソナライズ医療

第8章 南北アメリカの核酸増幅検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の核酸増幅検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの核酸増幅検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories Inc.
• Beckman Coulter, Inc.
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Eiken Chemical Co., Ltd.
• GE Healthcare
• Genomtec SA
• Grifols, S.A.
• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Jena Bioscience GmbH
• Lucigen Corporation
• Mast Group Ltd.
• Novartis AG
• OptiGene Limited
• PREMIER Biosoft
• QIAGEN GmbH
• Quidel Corporation
• Siemens Healthcare GmbH
• Sysmex Corporation
• TwistDx Limited

LIST OF FIGURES

• FIGURE 1. NUCLEIC ACID AMPLIFICATION TESTING MARKET RESEARCH PROCESS
• FIGURE 2. NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. NUCLEIC ACID AMPLIFICATION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. NUCLEIC ACID AMPLIFICATION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NUCLEIC ACID AMPLIFICATION TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NUCLEIC ACID AMPLIFICATION TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PROBE AMPLIFICATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SIGNAL AMPLIFICATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TARGET AMPLIFICATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC & MITOCHONDRIAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 29. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 49. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 101. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. POLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. QATAR NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 146. NUCLEIC ACID AMPLIFICATION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. NUCLEIC ACID AMPLIFICATION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Nucleic Acid Amplification Testing Market was valued at USD 3.13 billion in 2023, expected to reach USD 3.53 billion in 2024, and is projected to grow at a CAGR of 12.86%, to USD 7.30 billion by 2030.

Nucleic Acid Amplification Testing (NAAT) is a key molecular technique used to amplify and detect specific sequences of DNA or RNA, crucial for diagnosing infectious diseases, genetic disorders, and cancer. NAAT's necessity stems from its high sensitivity and specificity, enabling early detection and accurate diagnosis, which is vital for effective treatment and containment of diseases. Its applications span healthcare, biotechnology, and pharmaceuticals, playing an instrumental role in diagnostics, research, and development. The end-use scope includes hospitals, diagnostic laboratories, research institutions, and biopharmaceutical companies. Market growth is driven by the increasing prevalence of infectious diseases, technological advancements, and rising demand for personalized medicine. The COVID-19 pandemic significantly heightened awareness and adoption, positioning NAAT as an indispensable tool for viral detection. Emerging opportunities lie in the continuous integration of automation and digital technologies to enhance throughput and accuracy, along with expanding the scope in point-of-care (POC) diagnostics. However, market growth faces challenges such as high costs, complex regulatory landscapes, and a need for skilled personnel. Companies can capitalize on opportunities by investing in R&D to lower costs and improve accessibility, particularly in underserved regions. Collaborations with healthcare institutions and investment in training programs can mitigate some challenges. Areas ripe for innovation include the development of portable, user-friendly kits for POC testing and real-time analysis capabilities. Business growth can also be spurred by leveraging telemedicine and digital health technologies to streamline testing processes and data management. The market is competitive, with rapid innovations necessitating agility and strategic partnerships to capture market share effectively. Companies must focus on sustainability and cost-effectiveness to meet the growing demand while addressing existing limitations. Pioneering novel applications beyond disease detection, such as environmental monitoring and agricultural diagnostics, could unlock further market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Amplification Testing Market

The Nucleic Acid Amplification Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of COVID-19 and other infectious bacterial virus
  • Increasing investment for development of new biotechnological diagnostics
  • Expanding number of diagnostic facilities and labs
• Market Restraints
  • Stringent government regulation imposed on the nucleic acid amplification testing
• Market Opportunities
  • New technological improvements in NAA testing
  • Favorable government initiative to promote NAA testing
• Market Challenges
  • Lack of trained technical expertise and high sensitivity

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Amplification Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Amplification Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Amplification Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Amplification Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Amplification Testing Market

A detailed market share analysis in the Nucleic Acid Amplification Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Amplification Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Amplification Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Amplification Testing Market

A strategic analysis of the Nucleic Acid Amplification Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Amplification Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Beckman Coulter, Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Eiken Chemical Co., Ltd., GE Healthcare, Genomtec SA, Grifols, S.A., Hoffmann-La Roche Ltd., Illumina, Inc., Jena Bioscience GmbH, Lucigen Corporation, Mast Group Ltd., Novartis AG, OptiGene Limited, PREMIER Biosoft, QIAGEN GmbH, Quidel Corporation, Siemens Healthcare GmbH, Sysmex Corporation, and TwistDx Limited.

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Amplification Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technique, market is studied across Probe Amplification Systems, Signal Amplification Systems, and Target Amplification Systems.
• Based on Application, market is studied across Cancer, Genetic & Mitochondrial Disorders, Infectious Diseases, and Personalized Medicine. The Infectious Diseases is further studied across Bacterial and Viral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of COVID-19 and other infectious bacterial virus
    • 5.1.1.2. Increasing investment for development of new biotechnological diagnostics
    • 5.1.1.3. Expanding number of diagnostic facilities and labs
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent government regulation imposed on the nucleic acid amplification testing
  • 5.1.3. Opportunities
    • 5.1.3.1. New technological improvements in NAA testing
    • 5.1.3.2. Favorable government initiative to promote NAA testing
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of trained technical expertise and high sensitivity
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nucleic Acid Amplification Testing Market, by Technique

• 6.1. Introduction
• 6.2. Probe Amplification Systems
• 6.3. Signal Amplification Systems
• 6.4. Target Amplification Systems

7. Nucleic Acid Amplification Testing Market, by Application

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Genetic & Mitochondrial Disorders
• 7.4. Infectious Diseases
  • 7.4.1. Bacterial
  • 7.4.2. Viral
• 7.5. Personalized Medicine

8. Americas Nucleic Acid Amplification Testing Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Nucleic Acid Amplification Testing Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Nucleic Acid Amplification Testing Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories Inc.
• 2. Beckman Coulter, Inc.
• 3. Becton, Dickinson, and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Eiken Chemical Co., Ltd.
• 7. GE Healthcare
• 8. Genomtec SA
• 9. Grifols, S.A.
• 10. Hoffmann-La Roche Ltd.
• 11. Illumina, Inc.
• 12. Jena Bioscience GmbH
• 13. Lucigen Corporation
• 14. Mast Group Ltd.
• 15. Novartis AG
• 16. OptiGene Limited
• 17. PREMIER Biosoft
• 18. QIAGEN GmbH
• 19. Quidel Corporation
• 20. Siemens Healthcare GmbH
• 21. Sysmex Corporation
• 22. TwistDx Limited